

## Imugene successfully completes preclinical animal studies

---

- **Final audited preclinical toxicology and safety pharmacology reports received from Charles River Laboratories (USA)**
- **No adverse effects noted and high cancer fighting antibody responses generated in two species**

**Melbourne, Australia, 20 September 2016:** Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce it has received final audited preclinical reports from Charles River Laboratories in the US for its HER-Vaxx immunotherapeutic cancer vaccine, currently in development for gastric cancer.

The two studies, a repeat dose toxicology study in rats and a cardiovascular/respiratory safety pharmacology study in beagle dogs, were conducted under FDA accredited conditions. In both studies, no adverse effects were noted at doses which are higher than those to be used in the Phase Ib trial commencing imminently in 2016.

Importantly, as a critical marker for the vaccine working as expected, very strong cancer fighting antibodies were measured in the sera of both species.

Imugene COO Ms. Leslie Chong said, "This is yet another critical milestone met in our preparation for commencing our Phase 1B/2 clinical trial in patients with gastric cancer."

### **About Imugene**

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from several B cell epitopes of HER-2/neu. It has been shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

In January 2016 Imugene announced a new partnership with the Medical University of Vienna to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.

For further information, please visit [www.imugene.com](http://www.imugene.com).

Sign up to follow @TeamImugene on Twitter at <http://www.twitter.com/TeamImugene>.

To follow Imugene on Facebook visit [www.facebook.com/imugene](http://www.facebook.com/imugene).

### **For further information please contact:**

#### **Imugene:**

Leslie Chong, Chief Operating Officer

Tel: +61 458 040 433 (Australia), [leslie.chong\[at\]imugene.com](mailto:leslie.chong[at]imugene.com)